Brokers Issue Forecasts for TScan Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Research analysts at Wedbush issued their Q1 2025 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.26) for the quarter. Wedbush currently has a “Outperform” rating and a $10.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.04) per share. Wedbush also issued estimates for TScan Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS and Q4 2025 earnings at ($0.27) EPS.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.08. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. The firm had revenue of $7.21 million for the quarter, compared to the consensus estimate of $2.94 million.

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Thursday, March 7th.

TScan Therapeutics Stock Down 1.4 %

NASDAQ TCRX opened at $6.82 on Thursday. The stock’s 50-day moving average price is $7.06 and its 200-day moving average price is $5.67. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.18. TScan Therapeutics has a 52 week low of $1.62 and a 52 week high of $9.00. The company has a market capitalization of $326.54 million, a P/E ratio of -3.61 and a beta of 0.90.

Institutional Trading of TScan Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. BlackRock Inc. raised its stake in TScan Therapeutics by 1.4% during the 1st quarter. BlackRock Inc. now owns 1,519,188 shares of the company’s stock valued at $4,254,000 after purchasing an additional 20,650 shares during the period. Renaissance Technologies LLC purchased a new position in TScan Therapeutics during the 1st quarter valued at approximately $37,000. Woodline Partners LP grew its holdings in TScan Therapeutics by 37.1% during the 1st quarter. Woodline Partners LP now owns 136,930 shares of the company’s stock valued at $383,000 after buying an additional 37,030 shares in the last quarter. LPL Financial LLC purchased a new position in TScan Therapeutics during the 2nd quarter valued at approximately $50,000. Finally, Jane Street Group LLC purchased a new position in TScan Therapeutics during the 2nd quarter valued at approximately $32,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.